Ignite Creation Date:
2024-05-05 @ 9:22 PM
Last Modification Date:
2024-10-26 @ 10:04 AM
Study NCT ID:
NCT00878878
Status:
COMPLETED
Last Update Posted:
2012-08-24
First Post:
2009-04-08
Brief Title:
Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure PASP and Pulmonary Vascular Resistance PVR
Sponsor:
GE Healthcare
Organization:
GE Healthcare
Study Overview
Official Title:
A Phase 4 Placebo Controlled Single-blind Cross-over Safety Study to Evaluate the Effect of Optison on Pulmonary Artery Systolic Pressure PASP and Pulmonary Vascular Resistance PVR as Measured by Right Heart Catheterization
Status:
COMPLETED
Status Verified Date:
2012-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The design of this study is to conduct a comprehensive safety evaluation of the pulmonary hemodynamic effects of Optison The study is being conducted in subjects referred for cardiac catheterization for clinical reasons
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None